PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

Author's Avatar
Apr 27, 2023

Abstract selected as featured poster to be reviewed by expert panel in the Head and Neck Cancer discussion session